Last updated: February 21, 2026
What is the drug associated with NDC 68382-0271?
NDC 68382-0271 corresponds to Sotatercept, a biological agent developed by Acceleron Pharma. It is an investigational therapy primarily aimed at treating pulmonary arterial hypertension (PAH) and is in advanced clinical trials.
What is the development and approval status?
Sotatercept is not yet approved by the Food and Drug Administration (FDA). It has received Fast Track designation and is in Phase 3 clinical trials as of 2023. Market entry is anticipated within the next 12 to 24 months, dependent on trial outcomes and regulatory review.
What is the target market?
The potential market includes patients with pulmonary arterial hypertension (estimated at approximately 75,000 globally), particularly those with World Health Organization (WHO) Group 1 PAH. The treatment-relevant population in the United States accounts for roughly 15,000-20,000 diagnosed patients.
What are key competitors?
Approved therapies include riociguat (Adempas), macitentan (Opsumit), and epoprostenol (Flolan). These agents target endothelin pathways, prostacyclin pathways, or nitric oxide signaling. Sotatercept offers a novel mechanism of action—modulating activin signaling to reduce vascular remodeling.
What are the potential market entry strategies?
- Early access through provisional approvals or accelerated pathways.
- Pricing aligned with existing PAH therapies, considering high unmet needs.
- Incorporating value-based pricing based on clinical trial results demonstrating superior efficacy or safety.
How do clinical trial outcomes influence market potential?
Sotatercept has shown in trials a significant reduction in pulmonary vascular resistance. In Phase 2 studies, it improved exercise capacity and functional class. The FDA’s decision for approval will weigh efficacy, safety, and comparative benefit over existing options.
What are preliminary price estimates?
Pricing considerations:
- Current PAH therapies price from $70,000 to $150,000 annually per patient.
- Biologic agents tend to be at the higher end due to manufacturing complexity and patent protection.
Projected launch price range:
| Price Range |
Justification |
| $150,000 - $180,000 |
Similar to other biologics for chronic conditions, reflecting innovation and R&D investment. |
| $120,000 - $150,000 |
More conservative, aligned with current PAH therapeutic landscape. |
Initial pricing is expected to fall toward $150,000 annually, pending negotiations, payer coverage, and subsequent value assessments.
What factors influence future price trends?
- Clinical efficacy compared to existing therapies.
- Pharmacoeconomic assessments demonstrating cost-effectiveness.
- Competition from other novel therapies entering approval.
- Manufacturing costs and supply chain efficiency.
- Payer negotiations and formulary placements.
What are key regulatory and policy considerations?
- FDA's accelerated approval path could influence initial pricing.
- Payor coverage will depend on unmet need, trial results, and cost-effectiveness.
- Pricing adjustments may occur post-approval based on real-world data.
How does patent landscape affect pricing and market exclusivity?
Sotatercept's patent protection extends into the late 2030s, supporting exclusivity for approximately a decade post-launch. This period influences pricing strategies, with initial premium pricing justified by innovation and market protection.
Summary of market and price projections
| Timeline |
Milestone |
Estimated Price Range |
| Pre-approval (2024-2025) |
Near-completion of Phase 3 trials |
N/A |
| Approval (2025-2026) |
Regulatory approval and launch |
$150,000/year |
| 2026-2028 |
Market penetration and payer negotiations |
$130,000 - $150,000 |
| Post-approval (2028+) |
Reassessment based on real-world data |
Potential discounts/upsides |
Key Takeaways
- Sotatercept is in late clinical development with potential approval within 2 years.
- Market size for PAH is limited but high value, with an annual value estimate near $150,000 per patient.
- Competition is robust but with a novel mechanism may gain premium positioning.
- Initial pricing is projected at approximately $150,000 annually, subject to negotiations.
- Continued data from Phase 3 trials and real-world use will heavily influence pricing and market share.
FAQs
1. When is Sotatercept expected to launch?
Likely within 12 to 24 months after successful Phase 3 trial completion and regulatory approval, anticipated around 2025-2026.
2. How does Sotatercept’s mechanism differ from existing therapies?
It modulates activin signaling involved in vascular remodeling, providing a different approach compared to endothelin receptor antagonists or prostacyclins.
3. What factors could lower the drug’s price?
Poor efficacy data, safety concerns, or competitive launches could prompt price reductions or loss of exclusivity.
4. How does patent protection impact future pricing?
Patent protection until the late 2030s allows for significant pricing power during exclusivity.
5. What is the market size for PAH treatments?
Estimated at 75,000 worldwide, with 15,000-20,000 in the U.S., representing a high-value, niche market.
References
[1] FDA. (2023). Fast Track Designation for Sotatercept.
[2] GlobalData. (2023). Pulmonary Arterial Hypertension Market Report.
[3] IQVIA. (2022). US Pharmaceutical Pricing Data.
[4] Acceleron Pharma. (2022). Clinical Trial Reports on Sotatercept.
[5] WHO. (2021). Pulmonary Hypertension Data.
